Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. - Wikidata - wikimedia - TriplyDB

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

http://www.wikidata.org/entity/Q49211560

about

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment Pembrolizumab in classical Hodgkin's lymphoma Immunotherapy in hematologic malignancies: past, present, and future.Checkpoint inhibitors in hematological malignancies Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression.Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin's Lymphoma?Cancer immunotherapies targeting the PD-1 signaling pathway.Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.Chimeric antigen receptor T-cell therapies for lymphoma.PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.An Update on the Use of Immunotherapy in the Treatment of Lymphoma.Mechanisms of Immune Tolerance in Leukemia and Lymphoma.Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.Immunotherapy for the treatment of Hodgkin lymphoma.Emerging role of checkpoint blockade therapy in lymphoma.Immunogenomics: using genomics to personalize cancer immunotherapy.Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis.The emerging role of immune checkpoint inhibition in malignant lymphoma.Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.Novel treatment concepts in Hodgkin lymphoma.Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.Targeting the programmed death-1 pathway in lymphoid neoplasms.Novel agents in classical Hodgkin lymphoma.

P2860

Q26745842-160B2A5A-520D-4E67-B5C5-16E5C75974C4 Q28066941-31042FBF-BF06-4BE3-AF9C-82005D18FF02 Q28076294-3D05FF9F-4463-4F9D-B664-FEE983306B28 Q28079273-F0A2231E-1B93-4459-99FA-3E09720E4F4E Q33593865-F831E030-7DBD-4BB1-BFB6-1641BE4072E0 Q33651495-030E1A68-0E5C-45E9-8CF0-7DB86996D78A Q33704061-0313732C-D566-4046-87B3-360A3228B1AC Q33850467-61596F40-D0D7-4897-95A0-3C2CF9954EDC Q33886267-D542C4B9-52A1-4868-AB81-5E3268176021 Q36356089-67886172-3077-4DA1-A67C-46631FF5F30D Q37283336-F0547153-595E-4311-9BEC-BB71B730FCD3 Q37390723-E8D61875-3444-4D46-92B8-598E951695F0 Q37428061-9FF40B00-96F8-4EE5-AC95-FC89B7FAEA34 Q37589557-585D0D84-79CE-45FD-99AE-439728A24559 Q37593573-81B8FBB3-DB9D-40EB-8722-A2740A49CC53 Q37694536-FF95FE2E-254A-4FA3-8E6E-5D2D87869CE8 Q37737940-7D27C49F-5E39-4302-8D5E-FD277CD96E41 Q38402634-63833EE8-9158-433E-9FB3-445990BEE9D6 Q38600697-893BE157-648F-4D70-B42A-9FE1531E9F01 Q38607549-9B0BA651-3479-4737-8650-E742D54C1B48 Q38666304-E0DD4CA9-7924-4676-9D2F-DE15A37387B8 Q38683034-11C0B780-E632-499A-97BC-90853375F58D Q38687582-684A684C-446E-4BA3-A280-140602EB0612 Q38700459-703B0963-316D-48BD-B272-FB5D4A51E9DB Q38737641-9E43B6DF-85E2-453C-B91B-49D907C006D8 Q38756923-6CC4D107-053F-4D7B-951E-F6F523FB610B Q38772744-7D7F0164-5221-4EA9-BB8E-43B2D4EB9FC8 Q38781590-E246BEE6-8534-4B0D-86F4-667262522621 Q38791036-298CB7CC-6ED0-439E-9066-B6CF77C5EDA4 Q38793719-79FAC370-B7B2-4AA9-B36D-32B6930AF7D0 Q38868430-913811B4-920F-4008-89D0-120C1085719A Q38996724-195E3DD6-55BE-4938-A3AE-6F634B79967C Q39013253-6C888AD2-002F-4303-B521-54112AF5F760 Q39043082-7E4FB222-093D-40BB-ADD3-EEF0FBE25DAD Q39055861-25E05C52-4ADF-43C4-AC37-60D8463CBFA2 Q39069273-DD69C1E1-5B1B-4A6D-9FB7-55A6DDA5B9EC Q39072004-AAB33379-82F0-47A8-BCDF-93230E7E1139 Q39116985-BEBC7237-7F74-452F-ABDE-A99EF1322556 Q39153358-F58BA6BB-C807-4F47-BD6C-CAC304BA11F1 Q39187452-BC7D6E7D-4678-4301-B1DD-E98FD08934D6

P2860

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.

http://www.wikidata.org/entity/Q49211560

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Programmed Death-1 Blockade Wi ...... r Brentuximab Vedotin Failure.

@en

Programmed Death-1 Blockade Wi ...... r Brentuximab Vedotin Failure.

@nl

type

label

Programmed Death-1 Blockade Wi ...... r Brentuximab Vedotin Failure.

@en

Programmed Death-1 Blockade Wi ...... r Brentuximab Vedotin Failure.

@nl

prefLabel

Programmed Death-1 Blockade Wi ...... r Brentuximab Vedotin Failure.

@en

Programmed Death-1 Blockade Wi ...... r Brentuximab Vedotin Failure.

@nl

P1433

Q49211560-3AE40088-A645-4767-8065-41D88C163578

P1476

Q49211560-172941A7-632D-419B-9FE0-A210C4382A1B

P2093

Q49211560-2B7B86B7-DBFC-46B6-BB5A-4682C1E4F593

Q49211560-3E0371CA-5978-41B4-8E8D-B5D7C4C68B7E

Q49211560-5C2BE132-82E0-4364-B3E6-620543BA8F74

Q49211560-6E01E315-A087-44B7-A777-012CC6E2E904

Q49211560-835023DB-A43B-4E09-81BB-95928F88CBC3

Q49211560-83B0114C-6135-47AD-BE6C-2179BC277102

Q49211560-9911E6EF-27C3-4854-A1B9-6F58085CC313

Q49211560-9B36D14B-114C-41B7-BEBC-8B11C70FFB8B

Q49211560-D5FE175F-2846-49D6-85D0-A5B6AA4A921E

Q49211560-FA8A1B77-DA18-4085-B980-119CE3074491

P2860

Q49211560-024BBD97-6365-40E6-A658-1189A9F76388

Q49211560-04FF0A00-7466-4D5D-89AE-F1D0BC51BE7D

Q49211560-0BA5DDF5-AF99-48DB-81D5-52DC19E42686

Q49211560-1367FB9F-D34A-4E79-8F8B-3FA8663D9018

Q49211560-1F849106-0438-4B02-960C-B18A53330238

Q49211560-2352351D-8238-423E-8BB6-CB08272EF6C1

Q49211560-2E21ACBE-4924-438D-8B98-C8C14657A88A

Q49211560-3C6B1498-35B7-4B50-BDF9-534C4E654F94

Q49211560-62A7BCFF-6122-4CC9-B5DB-3F2C52993032

Q49211560-7893E683-3630-4B97-A4CB-88D284C6359F

P304

Q49211560-8BF3F57A-80E7-4C2E-B6FE-9F0E08BE07EE

P31

Q49211560-383732EE-0457-45D4-8FAB-B2DC3AAA6863

P356

Q49211560-9A3FD033-6B4A-42EC-9DAB-D76607044196

P407

Q49211560-64A6A5A2-4D26-41F2-A5EA-61706E0B4584

P433

Q49211560-90B8C829-85C2-43C8-9943-37F8084C2821

P478

Q49211560-C495C8AA-1C20-4816-857E-497306B8D108

P50

Q49211560-F6B55929-EC70-4D45-ACB0-C63CC1DB0D05

P577

Q49211560-B7F5A363-4111-4219-A449-81E16C3C92FC

P698

Q49211560-450BD1B1-0F6A-4810-872C-F95EA017FEEB

P932

Q49211560-39518FCD-32CC-491C-991B-F25642E4B7E8

P356

JCO.2016.67.3467

P1433

Journal of Clinical Oncology

P1476

Programmed Death-1 Blockade Wi ...... r Brentuximab Vedotin Failure.

@en

P2093

Alejandro D Ricart

http://www.w3.org/2001/XMLSchema#string

Arun Balakumaran

http://www.w3.org/2001/XMLSchema#string

Craig H Moskowitz

http://www.w3.org/2001/XMLSchema#string

Ellen S Snyder

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Michot

http://www.w3.org/2001/XMLSchema#string

John Kuruvilla

http://www.w3.org/2001/XMLSchema#string

Margaret A Shipp

http://www.w3.org/2001/XMLSchema#string

Philippe Armand

http://www.w3.org/2001/XMLSchema#string

Shelonitda Rose

http://www.w3.org/2001/XMLSchema#string

Vincent Ribrag

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

PD-1 and its ligands in tolerance and immunity

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Pembrolizumab for the treatment of non-small-cell lung cancer

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma.

P304

3733-3739

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2016.67.3467

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Pier Luigi Zinzani

P577

2016-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27354476

http://www.w3.org/2001/XMLSchema#string

P932

5791838

http://www.w3.org/2001/XMLSchema#string